Pharmacovigilance Risk Assessment Committee (PRAC): 31 August - 3 September 2026, European Medicines Agency, Amsterdam, the Netherlands, from 31 August 2026 to 3 September 2026

Pharmacovigilance Risk Assessment Committee (PRAC): 3 - 6 August 2026, European Medicines Agency, Amsterdam, the Netherlands, from 3 August 2026 to 6 August 2026

Pharmacovigilance Risk Assessment Committee (PRAC): 6 - 9 July 2026, European Medicines Agency, Amsterdam, the Netherlands, from 6 July 2026 to 9 July 2026

Pharmacovigilance Risk Assessment Committee (PRAC): 8 - 11 June 2026, European Medicines Agency, Amsterdam, the Netherlands, from 8 June 2026 to 11 June 2026

Pharmacovigilance Risk Assessment Committee (PRAC): 4 - 7 May 2026, European Medicines Agency, Amsterdam, the Netherlands, from 4 May 2026 to 7 May 2026

Pharmacovigilance Risk Assessment Committee (PRAC): 7 - 10 April 2026, European Medicines Agency, Amsterdam, the Netherlands, from 7 April 2026 to 10 April 2026

Pharmacovigilance Risk Assessment Committee (PRAC): 9 - 12 March 2026, European Medicines Agency, Amsterdam, the Netherlands, from 9 March 2026 to 12 March 2026

Pharmacovigilance Risk Assessment Committee (PRAC): 9 - 12 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 9 February 2026 to 12 February 2026

Pre-authorisation guidance under the Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6)

PSUSA/00000095/202312